Compare SPGI & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPGI | BMY |
|---|---|---|
| Founded | 1860 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.6B | 113.5B |
| IPO Year | 1994 | 2006 |
| Metric | SPGI | BMY |
|---|---|---|
| Price | $449.47 | $61.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 24 | 28 |
| Target Price | ★ $514.05 | $65.63 |
| AVG Volume (30 Days) | 1.7M | ★ 11.8M |
| Earning Date | 10-27-2026 | 10-29-2026 |
| Dividend Yield | 0.86% | ★ 4.00% |
| EPS Growth | 18.70 | ★ 178.46 |
| EPS | ★ 4.69 | 2.93 |
| Revenue | $6,063,000,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | N/A | $3.50 |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | $96.64 | ★ $21.49 |
| Revenue Growth | ★ 7.10 | N/A |
| 52 Week Low | $381.61 | $42.52 |
| 52 Week High | $552.25 | $68.64 |
| Indicator | SPGI | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 70.98 | 51.82 |
| Support Level | $402.49 | $59.91 |
| Resistance Level | $455.33 | $62.77 |
| Average True Range (ATR) | 8.31 | 1.81 |
| MACD | 5.90 | 0.50 |
| Stochastic Oscillator | 88.96 | 75.07 |
S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include energy (formerly commodity insights, this segment includes Platts and other data) and indexes. S&P spun off Mobility Global (Carfax and other auto data) on July 1, 2026.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.